Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis and John Hopkins Uni unite for allergy research

Sanofi-aventis has announced that it has teamed up with the Division of Allergy and Clinical Immunology at the John Hopkins University School of Medicine, Maryland under a three-year deal

Sanofi-aventis has announced that it has teamed up with the Division of Allergy and Clinical Immunology (ACI) at the John Hopkins University School of Medicine, Maryland under a three-year deal.

The partnership will undertake to develop new ways of treating respiratory diseases such as severe asthma and chronic obstructive pulmonary disease (COPD), along with immuno-allergic diseases.

For each research project, the two organisations will work on identifying new therapies, and will jointly design potential clinical studies and select biomarkers.

"This collaboration will allow sanofi-aventis and John Hopkins ACI to join their efforts to identify new therapeutic approaches, in particular in severe asthma and COPD," said Dr Marc Cluzel, senior vice president of research and development at sanofi-aventis.

Traditional treatment methods such as high dose inhaled steroids are not effective in all severe asthma sufferers. A better understanding of the effect the disease has on the functions of various cells in the body is needed in order to develop innovative therapies for these patients.

17th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics